CSL agrees to buy Swiss firm Vifor Pharma for $11.7bn
The acquisition is expected to expand CSL’s offering across a portfolio focused on renal disease, and iron deficiency…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Dec 21
The acquisition is expected to expand CSL’s offering across a portfolio focused on renal disease, and iron deficiency…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 21
Arena is a clinical-stage pharmaceutical company involved in the development of potential therapies for the treatment of several…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Dec 21
The acquisition will enable Thermo Fisher to provide a complete suite of discovery, clinical trial logistics, development and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Dec 21
The transaction will enable Alvotech to further invest in its platform and portfolio, and support its goal of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Dec 21
The expanded EUA was based on safety and efficacy data of paediatric and infant patients in Phase 2/3…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 21
According to the British drugmaker, Lynparza is the first medicine targeting BRCA mutations that showed clinical benefit in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Nov 21
With the divestments of UK oral liquid products, Essential Pharma expects to streamline its portfolio and advance its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 21
The financing from Blackstone will support Autolus’ clinical development of obe-cel for relapsed / refractory adult ALL and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Nov 21
In the Phase 2/3 trial, Paxlovid reduced 89% risk of Covid-19-related hospitalisation or death compared to placebo, within…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Nov 21
Novartis will sell 53.3 million bearer shares of Roche’s common stock, bringing an end to its investment in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates